Articles Tagged With: zuranolone
-
Zuranolone Therapy for Depression in the Postpartum Period
Zuranolone was well tolerated and resulted in substantial improvement of depressive symptoms in the postpartum period, suggesting that it may be a promising new oral therapy for postpartum depression.
-
Zuranolone Capsules (Zurzuvae)
Zuranolone can be prescribed to treat postpartum depression.
-
Postpartum Depression Medication Headed to Market
FDA approves first oral solution.
-
Zuranolone Trial Shows Early Promise as an Oral Neuroactive Steroid for the Treatment of Postpartum Depression
Zuranolone was approved by the Food and Drug Administration for the treatment of postpartum depression (PPD) in March 2019. One potential factor identified in PPD etiology is the dramatic perinatal changes in circulating levels of allopregnanolone, a neuroactive steroid with gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator properties. In brain regions associated with emotion and self-perception, neural network connectivity supported by GABAergic signaling is positively correlated with plasma allopregnanolone concentrations in individuals with PPD vs. healthy postpartum female individuals.